Longeveron Announces Full-Year 2024 Financial Results and Provides Business Update
Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ (laromestrocel) in Hypoplastic Left…
Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025
February 20, 2025 17:00 ET | Source: Tarsus Pharmaceuticals, Inc IRVINE, Calif.,…
MKS Instruments Reports Fourth Quarter and Full-Year 2024 Financial Results
Quarterly revenue of $935 million, above the midpoint of guidance Quarterly GAAP…
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update
February 06, 2025 16:30 ET | Source: Ultragenyx Pharmaceutical Inc. NOVATO, Calif.,…
EssilorLuxottica: Full-Year 2024 Results Conference Call Invitation
Full-Year 2024 ResultsConference Call Invitation Mr FRANCESCO MILLERI, Chairman and Chief Executive…